TIMolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (TIM-HHT)—A Prospective, Randomized, Double-Blind, Controlled, Cross-Over Trial

To date, there is no approved local therapeutic agent for the treatment of epistaxis due to hereditary hemorrhagic telangiectasia (HHT). Several case reports suggest the topical use of timolol. This monocentric, prospective, randomized, placebo-controlled, double-blinded, cross-over study investigat...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kornelia E. C. Andorfer, Florian Zeman, Michael Koller, Judith Zeller, René Fischer, Caroline T. Seebauer, Veronika Vielsmeier, Christopher Bohr, Thomas S. Kühnel
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-10-01
Edice:	Pharmaceutics
Témata:	timolol nasal spray HHT hereditary hemorrhagic telangiectasia Morbus Osler orphan disease
On-line přístup:	https://www.mdpi.com/1999-4923/14/11/2335
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!